Sirona Biochem Update to Shareholders on Financial Status and Operations
Sirona Biochem (TSX-V: SBM) announced significant operational and financial challenges. The company's recent convertible debenture financing attempt failed to secure sufficient investor participation, following a similar unsuccessful attempt last year. The previously announced investment agreement with Promura GmbH has fallen through, with committed funds never materializing.
Due to financial constraints, Sirona has initiated the liquidation of its subsidiary TFChem, resulting in the permanent closure of laboratory operations. The company is under a cease trade order since March 7, 2025. Additionally, Allergan Aesthetics has withdrawn from the TFC-1067 license agreement originally announced in June 2022. Management is currently evaluating options for potential future development while operating without salaries.
Sirona Biochem (TSX-V: SBM) ha annunciato gravi difficolt脿 operative e finanziarie. Il recente tentativo di finanziamento tramite obbligazioni convertibili non ha ottenuto un'adeguata partecipazione da parte degli investitori, replicando un insuccesso simile dello scorso anno. L'accordo di investimento precedentemente annunciato con Promura GmbH 猫 saltato, poich茅 i fondi promessi non si sono mai concretizzati.
A causa delle restrizioni finanziarie, Sirona ha avviato la liquidazione della sua controllata TFChem, con la conseguente chiusura definitiva delle attivit脿 di laboratorio. La societ脿 猫 soggetta a un ordine di sospensione delle negoziazioni dal 7 marzo 2025. Inoltre, Allergan Aesthetics si 猫 ritirata dall'accordo di licenza TFC-1067 originariamente annunciato nel giugno 2022. La direzione sta valutando opzioni per un possibile sviluppo futuro, operando nel frattempo senza percepire stipendi.
Sirona Biochem (TSX-V: SBM) anunci贸 importantes desaf铆os operativos y financieros. El reciente intento de financiamiento mediante bonos convertibles no logr贸 asegurar la participaci贸n suficiente de inversores, tras un intento similar fallido el a帽o pasado. El acuerdo de inversi贸n previamente anunciado con Promura GmbH se ha cancelado, ya que los fondos comprometidos nunca se materializaron.
Debido a limitaciones financieras, Sirona ha iniciado la liquidaci贸n de su subsidiaria TFChem, lo que ha resultado en el cierre permanente de las operaciones de laboratorio. La empresa est谩 bajo una orden de suspensi贸n de comercio desde el 7 de marzo de 2025. Adem谩s, Allergan Aesthetics se retir贸 del acuerdo de licencia TFC-1067 anunciado originalmente en junio de 2022. La direcci贸n est谩 evaluando opciones para un posible desarrollo futuro mientras opera sin salarios.
Sirona Biochem (TSX-V: SBM)鞚� 鞁皝頃� 鞖挫榿 氚� 鞛爼鞝� 鞏措牑鞗�鞚� 氚滍憸頄堨姷雼堧嫟. 斓滉芳 鞝勴櫂靷眲(financing convertible debenture) 臁半嫭 鞁滊弰臧� 韴瀽鞛� 彀胳棳 攵�臁膘溂搿� 鞁ろ尐頄堨溂氅�, 鞚措姅 鞛戨厔鞚� 鞙犾偓頃� 鞁滊弰 鞁ろ尐鞐� 鞚挫潃 瓴瓣臣鞛呺媹雼�. 鞚挫爠鞐� 氚滍憸霅� Promura GmbH鞕�鞚� 韴瀽 瓿勳暯鞚� 鞎届啀霅� 鞛愱笀鞚� 鞁れ牅搿� 鞚措（鞏挫歆� 鞎婌晞 氍挫偘霅橃棃鞀惦媹雼�.
鞛爼鞝� 鞝滌暯鞙茧 鞚疙暣 Sirona電� 鞛愴殞靷� TFChem鞚� 觳偘鞚� 鞁滌瀾頄堨溂氅�, 鞚措 鞚疙暣 鞁ろ棙鞁� 鞖挫榿鞚� 鞓侁惮鞝侅溂搿� 膦呺霅橃棃鞀惦媹雼�. 須岇偓電� 2025雲� 3鞗� 7鞚茧秬韯� 瓯半灅 欷戩 氇呺牴鞚� 氚涥碃 鞛堨姷雼堧嫟. 霕愴暅 Allergan Aesthetics電� 2022雲� 6鞗旍棎 氚滍憸霅� TFC-1067 霛检澊靹犾姢 瓿勳暯鞐愳劀 觳犿殞頄堨姷雼堧嫟. 瓴届榿歆勳潃 順勳灛 旮夓棳 鞐嗢澊 鞖挫榿頃橂┐靹� 頄ロ泟 臧滊皽 臧�電レ劚鞐� 雽�頃� 鞓奠厴鞚� 韽夑皜 欷戩瀰雼堧嫟.
Sirona Biochem (TSX-V : SBM) a annonc茅 d'importants d茅fis op茅rationnels et financiers. La r茅cente tentative de financement par d茅bentures convertibles n'a pas r茅ussi 脿 obtenir une participation suffisante des investisseurs, apr猫s un 茅chec similaire l'ann茅e derni猫re. L'accord d'investissement pr茅c茅demment annonc茅 avec Promura GmbH a 茅chou茅, les fonds promis ne s'茅tant jamais mat茅rialis茅s.
En raison de contraintes financi猫res, Sirona a lanc茅 la liquidation de sa filiale TFChem, entra卯nant la fermeture d茅finitive des op茅rations de laboratoire. La soci茅t茅 est soumise 脿 une ordonnance de suspension de n茅gociation depuis le 7 mars 2025. De plus, Allergan Aesthetics s'est retir茅 de l'accord de licence TFC-1067 initialement annonc茅 en juin 2022. La direction 茅value actuellement des options pour un d茅veloppement futur potentiel tout en op茅rant sans salaires.
Sirona Biochem (TSX-V: SBM) hat erhebliche operative und finanzielle Herausforderungen bekannt gegeben. Der j眉ngste Versuch einer Finanzierung durch wandelbare Schuldverschreibungen scheiterte an unzureichender Investorenbeteiligung, 盲hnlich wie bereits im Vorjahr. Die zuvor angek眉ndigte Investitionsvereinbarung mit Promura GmbH ist gescheitert, da die zugesagten Mittel nie eingingen.
Aufgrund finanzieller Einschr盲nkungen hat Sirona die Liquidation seiner Tochtergesellschaft TFChem eingeleitet, was zur dauerhaften Schlie脽ung der Laborbetriebe f眉hrt. Das Unternehmen steht seit dem 7. M盲rz 2025 unter einem Handelsstopp. Zudem hat sich Allergan Aesthetics aus dem im Juni 2022 angek眉ndigten Lizenzvertrag TFC-1067 zur眉ckgezogen. Das Management pr眉ft derzeit Optionen f眉r eine potenzielle zuk眉nftige Entwicklung und arbeitet dabei ohne Geh盲lter.
- None.
- Failed convertible debenture financing due to insufficient investor participation
- Promura GmbH investment agreement fell through with no funds received
- Subsidiary TFChem entering liquidation with permanent closure of laboratory operations
- Cease trade order issued on March 7, 2025
- Allergan Aesthetics terminated the TFC-1067 license agreement
- Management operating without salary and personally funding operations
VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (鈥淪irona鈥�) wishes to provide shareholders with a critical update on the company鈥檚 financial position and recent corporate developments.
The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.
After an extensive search for strategic investment, Sirona entered into an investment agreement with Promura GmbH, also announced on April 22, 2025. This decision followed a detailed due diligence process, including a review of Promura GmbH and its principal, Mr. Markus Burbach. Despite multiple assurances and repeated delays, the funds committed under this agreement were never received. Sirona has now concluded that the investment will not materialize.
In light of limited financing options, Sirona has made the difficult decision to allow for the orderly liquidation of its wholly owned subsidiary, TFChem, in accordance with French bankruptcy regulations. All laboratory operations have ceased, and the facility is now permanently closed. Sirona is also facing ongoing financial pressures, which led to the issuance of a cease trade order on March 7, 2025.
Additionally, Sirona has been informed that Allergan Aesthetics will not be proceeding with the license agreement announced on June 13, 2022, regarding the commercialization of TFC-1067. Sirona values the experience gained through this collaboration and appreciates the opportunity to have worked with a global leader in medical aesthetics.
Despite ongoing and significant challenges, management acknowledges that the commercial potential of its proprietary technologies remains uncertain. Nevertheless, it is evaluating structural and financial options that could, if feasible, support their future development.
About Sirona Biochem
Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona鈥檚 compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona鈥檚 laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit .
Investor Enquiries:
Christopher Hopton
Chief Financial Officer
Phone: (604) 641-4466
Email: [email protected]
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
This news release includes certain statements that may be deemed 鈥渇orward-looking statements鈥�. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 鈥渆xpects鈥�, 鈥減lans鈥�, 鈥渁nticipates鈥�, 鈥渂elieves鈥�, 鈥渋ntends鈥�, 鈥渆stimates鈥�, 鈥減rojects鈥�, 鈥減otential鈥� and similar expressions, or that events or conditions 鈥渨ill鈥�, 鈥渨ould鈥�, 鈥渕ay鈥�, 鈥渃ould鈥� or 鈥渟hould鈥� occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company鈥檚 management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
FAQ
What led to Sirona Biochem's (SRBCF) subsidiary TFChem liquidation in 2025?
Why did Allergan Aesthetics terminate its license agreement with Sirona Biochem?
What is the current trading status of Sirona Biochem (SRBCF) stock?
How is Sirona Biochem's management handling the company's financial crisis?
What happened to the Promura GmbH investment in Sirona Biochem?
